LAVAL, Quebec —Neptune Technologies & Bioressources has been granted a new continuation patent pertaining to the treatment of Alzheimer’s through phospholipids.
The patent (U.S. Patent No. 8,680,080) is valid until 2022 and focuses on treating Alzheimer’s disease by administering an effective amount of a phospholipid composition, wherein the phospholipid composition comprises docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). This is Neptune's first patent specifically targeting a neurological condition.
“Neurological disorders, such as Alzheimer’s, are growing and new methods to prevent and treat such conditions using alternative treatments are continuously being sought out," said Henri Harland, president and CEO of Neptune. "In addition to Neptune, this new patent substantially benefits our subsidiary, NeuroBioPharm, as it continues to develop omega-3 phospholipid products for neurological pharmaceutical applications."